Approval · Notice of Compliance 19687 · 2017
ESTALIS: Notice of Compliance 19687
Issued August 21, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19687
- Date
- August 21, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the warning and precautions section of the product monograph and package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESTALIS | Not yet assigned | — |
Medicinal ingredients
- NORETHINDRONE ACETATE 2.7 MG per PATCH
- ESTRADIOL HEMIHYDRATE 0.62 PER
- NORETHINDRONE ACETATE 4.8 MG per PATCH
- ESTRADIOL HEMIHYDRATE 0.512 PER